We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

At least nine patients using the glucagon-like peptide 1 (GLP-1) receptor agonists semaglutide and tirzepatide developed ophthalmic complications, of whom seven had nonarteritic anterior ischemic ...

Collagen, the body's most abundant protein, has long been viewed as a predictable structural component of tissues. However, a ...

“Three-Peat” is just one of many. By Adeel Hassan The Kansas City Chiefs are aiming to win their third consecutive Super Bowl on Sunday and become the first team to pull off a Super Bowl ...

In the 176-week study run over three years – which underpinned tirzepatide's approval for obesity last year – once-weekly injections of tirzepatide at three dose levels – 5, 10, and 15 mg ...

After a median follow-up of two years and a maximum of three years, cardiovascular death or worsening heart failure events occurred in 9.9% of the tirzepatide group and 15.3% of those taking placebo.

Bronny James hit the first three-pointer of his NBA career in the Lakers' win over the Clippers, giving Savannah James a proud mom moment. During the Lakers' 122-97 win over the Clippers ...

According to research, these ... Tirzepatide Shows Powerful Diabetes-Prevention Effect in Three-Year Trial Nov. 26, 2024 — Tirzepatide, a new injectable weight-loss drug, reduced the risk of ...